Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 1:273:552-561.
doi: 10.1016/j.jad.2020.04.061. Epub 2020 May 3.

Neurochemical correlates of behavioral treatment of pediatric trichotillomania

Affiliations
Review

Neurochemical correlates of behavioral treatment of pediatric trichotillomania

Tara S Peris et al. J Affect Disord. .

Abstract

Background: Trichotillomania (TTM) is a chronic and impairing psychiatric disorder with suspected dysfunctional cortico-striato-thalamo-cortical (CSTC) circuit activity reflecting excitatory/inhibitory signaling imbalance. TTM neurochemistry is understudied, with no prior research using magnetic resonance spectroscopy (MRS). This pilot investigation examined associations between TTM diagnosis, symptom severity, and response to behavioral treatment with MRS neurometabolites glutamate (Glu) and γ-aminobutyric acid (GABA) in CSTC structures.

Methods: Proton echo-planar spectroscopic imaging (PEPSI) MRS was acquired from bilateral pregenual anterior cingulate cortex (pACC), caudate, putamen, globus pallidus, thalamus, and proximal white matter in 10 unmedicated girls with TTM, ages 9-17 years, before and after treatment, and from 13 age- and sex-matched healthy controls.

Results: Nine of 10 TTM patients were treatment responders. Pretreatment mean Glu and GABA did not differ significantly between participants and controls. Pretreatment TTM symptoms were correlated with Glu in (left + right) pACC (r = 0.88, p = 0.02) and thalamus (r = 0.82, p = 0.012), and were negatively correlated with pACC GABA (r = -0.84, p = 0.034). Mean GABA in putamen increased 69% (baseline to post-treatment) (p = 0.027). Higher pretreatment Glu in caudate, putamen, globus pallidus, and thalamus predicted greater symptom decreases with treatment (all r < -0.6, p < 0.05); higher caudate GABA predicted less treatment-related symptom decline (r = 0.86, p = 0.014).

Limitations: Small sample, GABA quantified with spectral fitting rather than editing.

Conclusion: Consistent with other neuroimaging, MRS reveals discrete CSTC chemical changes with effective behavior therapy, and possibly with TTM etiology. TTM symptoms relate to excess excitatory versus inhibitory signaling in pACC and thalamus; symptom improvement may reflect reduced excitatory drive of the CSTC direct-pathway activity.

Keywords: Behavioral treatment; Children; GABA; Glutamate; MRS; Trichotillomania (hair-pulling disorder).

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Peris receives funding from the National Institutes of Mental Health (NIMH) and the TLC Foundation for Body Focused Repetitive Behavior and royalties from Oxford University Press. Dr. McCracken reports receiving consultant income from Roche, Octapharma, and GW Biosciences; research clinical trial contracts from Roche, Think Now, Inc, and NICHD; and payment for expert witness participation for Lannett Pharmaceuticals. Dr. Piacentini has received grant or research support from NIMH, the TLC Foundation for Body-focused Repetitive Behaviors, the Tourette Association of America, and Pfizer Pharmaceuticals through the Duke University Clinical Research Institute Network. He receives publication royalties from Guilford Press and Oxford University Press. He receives speaking honoraria and/or travel support from the Tourette Association of America, the International Obsessive Compulsive Disorder Foundation, and the TLC Foundation for Body-focused Repetitive Behaviors.

Publication types

LinkOut - more resources